Get started
Annovis Bio, Inc.Annovis Bio, Inc.Annovis Bio, Inc.

Annovis Bio, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ANVS chart


Full chart

ANVS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪61.54 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.85 USD
Net income (FY)
‪−56.20 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪10.98 M‬
Beta (1Y)
5.07

Employees


Employees (FY)
6
Change (1Y)
+1 +20.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−9.37 M‬ USD

About Annovis Bio, Inc.


Sector
Health Technology
CEO
Maria-Luisa Maccecchini
Headquarters
Malvern
Website
annovisbio.com
Founded
2008
FIGI
BBG00PN9XD40
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ANVS news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ANVS is 5.01 USD — it has increased by 2.06% in the past 24 hours. Watch Annovis Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Annovis Bio, Inc. stocks are traded under the ticker ANVS.
ANVS stock has fallen by −15.05% compared to the previous week, the month change is a −34.89% fall, over the last year Annovis Bio, Inc. has showed a −55.47% decrease.
We've gathered analysts' opinions on Annovis Bio, Inc. future price: according to them, ANVS price has a max estimate of 72.00 USD and a min estimate of 21.00 USD. Watch ANVS chart and read a more detailed Annovis Bio, Inc. stock forecast: see what analysts think of Annovis Bio, Inc. and suggest that you do with its stocks.
ANVS reached its all-time high on Jul 23, 2021 with the price of 132.00 USD, and its all-time low was 2.42 USD and was reached on Mar 23, 2020. View more price dynamics on ANVS chart.
See other stocks reaching their highest and lowest prices.
ANVS stock is 16.59% volatile and has beta coefficient of 5.07. Track Annovis Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Annovis Bio, Inc. there?
Today Annovis Bio, Inc. has the market capitalization of ‪61.54 M‬, it has decreased by −12.72% over the last week.
Yes, you can track Annovis Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Annovis Bio, Inc. is going to release the next earnings report on Apr 8, 2025. Keep track of upcoming events with our Earnings Calendar.
ANVS earnings for the last quarter are −0.97 USD per share, whereas the estimation was −0.68 USD resulting in a −42.05% surprise. The estimated earnings for the next quarter are −0.32 USD per share. See more details about Annovis Bio, Inc. earnings.
Annovis Bio, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ANVS net income for the last quarter is ‪−12.64 M‬ USD, while the quarter before that showed ‪−5.02 M‬ USD of net income which accounts for −151.74% change. Track more Annovis Bio, Inc. financial stats to get the full picture.
No, ANVS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 6.00 employees. See our rating of the largest employees — is Annovis Bio, Inc. on this list?
Like other stocks, ANVS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Annovis Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Annovis Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Annovis Bio, Inc. stock shows the sell signal. See more of Annovis Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.